Abbott plans to acquire Cephea Valve Technologies, a company developing a transcatheter mitral valve replacement (TMVR) device, the Chicago-area healthcare giant announced Jan. 16.

Will operators be able to replicate COAPT’s restraint and its outcomes?

Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.

Three decades after the first Transcatheter Cardiovascular Therapeutics conference, TCT.18’s organizers are moving “toward a more practical approach,” says Cardiovascular Research Foundation CEO Juan Granada, MD.

Patients hospitalized with acute myocardial infarction (AMI) actually fare better when some of the top minds in interventional cardiology are away at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, suggests a study published March 9 in the Journal of the American Heart Association.

Could the ORBITA trial’s enduring value be in prompting the cardiology community to rethink how it diagnoses, treats and even defines angina?

DENVER — Measuring frailty could lead to more accurate predictions of outcomes following transcatheter aortic valve replacement (TAVR) than a validated risk algorithm, according to research presented Oct. 30 at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

The 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium kicks off in Denver in less than two weeks. In preparation, Gregg W. Stone, MD, co-director of medical research and education at the Cardiovascular Research Foundation, provided some expected highlights of this year’s session Oct. 16 during a press briefing.